^
BIOMARKER:

IFNG gene signature overexpression

News
Twitter
Trials
IFNG gene signature overexpression
Lymphoma
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
Head and Neck Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
Cervical Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
Urothelial Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
Melanoma
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
Pancreatic Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
RCC
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
IFNG gene signature overexpression
Melanoma
nivolumab + 4SC-202
Sensitive: C3 – Early Trials